IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

Core Insights - IDEAYA Biosciences announced the publication of abstracts for presentations on IDE275 (GSK959) at the AACR Annual Meeting, highlighting its potential as a best-in-class Werner Helicase inhibitor for treating high microsatellite instability (MSI-H) solid tumors [1][2][3] Company Overview - IDEAYA Biosciences is focused on precision medicine in oncology, developing targeted therapeutics based on molecular diagnostics [9] - The company collaborates with GSK, which is responsible for 80% of the global research and development costs for IDE275 (GSK959) [4] Product Development - IDE275 (GSK959) has shown selective preclinical efficacy in MSI-H solid tumors, with significant prevalence rates of approximately 31% in endometrial, 20% in colorectal, and 19% in gastric cancers [3][7] - The drug is currently in a Phase 1 dose escalation trial in partnership with GSK, with the potential for further clinical development as both a monotherapy and in combination with PD1 inhibitors [2][7] Financial Aspects - IDEAYA could earn a $10 million milestone payment upon the initiation of Phase 1 clinical dose expansion and is eligible for up to$465 million in future milestone payments [4] - Upon commercialization, IDEAYA stands to receive up to $475 million in commercial milestones, 50% of U.S. net profits, and tiered royalties on global non-U.S. net sales of IDE275 [4] Upcoming Presentations - At the AACR 2025, IDEAYA will present a total of 8 presentations across various programs, including 4 focused on IDE275 (GSK959) [5][7]